MGC PHARMACEUTICALS LTD Forum: Community User: Ramos

https://stockhead.com.au/health/the-uk-rolls-out-the-welcome-mat-to-mgc-pharmas-epilepsy-treatment/

Mit England ist eine Mega Sache. Ich bin sehr gespannt.

So langsam startet MGC.

Ich bin in MGC.

Liest hier jemand?

Wie siehst du die zukünftige Entwicklung?

Ja schon drei Jahre

Jemand hier investiert? :)

GMP Certification and Manufacturing Licence Awarded to MXC’s European Facility Production of Pharma Grade Medicinal Cannabis Products to Commence  MXC’s European medicinal cannabis compounding and manufacturing facility is now fully GMP certified, and in addition also awarded the manufacturing licence for the production of medicinal cannabis based medicines, completing major milestones for the Company  The facility can now be considered one of the most advanced in Europe for the compounding and manufacturing of medicinal cannabis products, at pharmaceutical grade  Receipt of manufacturing licence demonstrates the facility complies with strict European production quality standards for production process of pharmaceutical grade medicinal cannabis  The immediate production of pharmaceutical grade medicinal cannabis medicines can now commence  Signals ability to immediately commence full scale manufacturing operation of CannEpilTM - for final, independent validation before exportation into Australasia and Europe  MXC can now design and produce additional GMP grade medical cannabis medicines targeting a range of conditions, and supporting research, across the entire MGC group, providing strong potential for new product development and future revenue streams MGC Pharmaceuticals Ltd (ASX: MXC or “the Company”) is pleased to announce that it has received its GMP certification and formal manufacturing licence to produce Good Manufacturing Practice (GMP) grade medical cannabis medicines containing THC and CBD APIs at its European production and compounding facility. The Company can immediately commence production under this manufacturing licence for pharmaceutical grade products. MXC has reached this major milestone from final tests on the first batch of drug-resistant epilepsy medication - CannEpilTM, now completed, resulting in receipt of this formal manufacturing licence for its European facility. The awarding this licence signifies compliance with strict European quality standards for production and manufacturing of pharmaceutical grade products and the handling of cannabis based medicines. To date, the Company has received strong industry support ahead of production and supply of the first batch of CannEpilTM, highlighting the growth potential of MXC and its strategy in the global BioPharma sector. This full GMP certification and formal manufacturing license represents completion of the final step ahead of starting commercial scale production and makes MXC’s one of the most advanced facilities of its kind, within Europe. Importantly, receipt of the formal manufacturing licence also permits MXC to produce additional medicinal cannabis based pharmaceutical products, for use by MXC in clinical studies, research pipelines and product development. These will be distributed into the global market and target the increasing demand for such products. Roby Zomer, Co-founder and Managing Director, MGC Pharmaceuticals commented: “We are delighted to have been awarded our formal GMP Certificate and manufacturing licence and to commence production at our cutting edge European Facility, this is one more step in our Seed to Pharma strategy to become a leading BioPharma company with formulated medicines to sell into the global market”. --Ends—

So mal sehen ob im Februar schon die ersten 100% kommen :)

We are very excited to announce that MGC Pharma has been granted interim Good Manufacturing Practice (GMP) Certification for our European Manufacturing Facility. This means that we are now able to begin production of CannEpil™ at the facility and distribute it across Australia. This is expected to generate in excess of $1 million in sales in the first year. The interim GMP Certification follows 18 months of construction and work at the facility, and as soon as we receive full GMP Certification, it will be one of the most advanced facilities in Europe for pharmaceutical grade Medical Cannabis production. Click to read the full announcement here: http://bit.ly/2Bs2uhd

MXC welcomes the Australian government move to legalise Medicinal Cannabis exports. The decision is expected to strengthen commercial opportunities for domestic producers and means that MXC will now intensify its focus and fast track plans on developing a pharmaceutical grade Medicinal Cannabis cultivation and manufacturing strategy in Australia, to complement its existing operations in Europe. An Australian operational base has always been part of the Company’s longer-term strategy, but not until Federal legislative changes made it commercially viable to access key export markets. The first of MXC's Australian products will be our Medical Cannabis epilepsy product CannEpil during 2018. Following yesterday’s announcement by the Federal Health Minister Greg Hunt, MXC hopes in future years to be able to supply CannEpil and other pharmaceutical grade products directly to the Australian market from a future Australian based operation. The opening up of export opportunities for Australian producers means that in addition to supplying its Australian pharmaceutical pipeline, MXC would be able to expand into the sale of Australian manufactured Medical Cannabis products such as CannEpil into global markets, where an Australian operation would provide significant cost and logistics benefits to export into key Asia Pacific markets over MXC’s European operations. Read the full announcement here: http://www.investi.com.au/api/announcements/mxc/90ff4aff-c6c.pdf

Und ab geht's :)

Es soll keine Übernahme geben aber sie könnten ins Licht von größeren Unternehmen rücken wenn im Februar alles in Sack und Tüten ist.

Soll das Geschäft übernommen werden? Weiß jemand was?

Da hat sich jemand ein wenig eingedeckt :)